RecruitingNCT06793397
CYB003 with psychological support for major depression
About this title
Read the official source — NCT06793397This study evaluates the safety and effectiveness of CYB003 for people with depression.
Medication studyAges 18–85Multiple countries
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of CYB003 for people with depression.
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 85 years. Other eligibility criteria apply.
- Listed locations
- Birmingham and 78 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: December 10, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 330
- Sponsor
- Cybin IRL Limited
- Sponsor type
- Unknown or unclear
- Study type
- Behavioral
- Intervention type
- Psychotherapy / behavioral intervention, Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Australia, United Kingdom, ...
- Age range
- From 18 Years to 85 Years
- Official registry ID
- NCT06793397
- Official title
Show the full official title
An Efficacy and Safety, Phase III, Multi-center, Double-Blind, Randomized Controlled Study Comparing 2 Active Doses of CYB003 and Placebo in Eligible Participants With Major Depressive Disorder
Recruitment & locations
RecruitingBirmingham, United States · Gilbert, United States · Little Rock, United States
64 more locations
- Glendale, United States
- Imperial, United States
- Los Angeles, United States
- Orange, United States
- San Juan Capistrano, United States
- Santa Monica, United States
- Stanford, United States
- New Haven, United States
- Jacksonville, United States
- Maitland, United States
- Naples, United States
- Tampa, United States
- Atlanta, United States
- Marietta, United States
- Chicago, United States
- Marrero, United States
- New Orleans, United States
- Baltimore, United States
- Rockville, United States
- Boston, United States
- Watertown, United States
- Eden Prairie, United States
- Golden Valley, United States
- Las Vegas, United States
- Toms River, United States
- New York, United States
- The Bronx, United States
- Oklahoma City, United States
- Philadelphia, United States
- Austin, United States
- DeSoto, United States
- Fort Worth, United States
- Houston, United States
- San Antonio, United States
- Everett, United States
- Seattle, United States
- Camperdown, Australia
- Maroochydore, Australia
- Melbourne, Australia
- Notting Hill, Australia
- Prague, Czechia
- Předměstí, Czechia
- Homburg, Germany
- Berlin, Germany
- Frankfurt am Main, Germany
- Mannheim, Germany
- Athens, Greece
- Thessaloniki, Greece
- Dublin, Ireland
- Galway, Ireland
- Bialystok, Poland
- Bydgoszcz, Poland
- Gdansk, Poland
- Warsaw, Poland
- Cambridge, United Kingdom
- Doncaster, United Kingdom
- Edinburgh, United Kingdom
- Glasgow, United Kingdom
- Liverpool, United Kingdom
- London, United Kingdom
- Newcastle upon Tyne, United Kingdom
- Reading, United Kingdom
- Sheffield, United Kingdom
- Czechia
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of CYB003 for people with depression.
Who is behind this study?
The study sponsor is Cybin IRL Limited.
Does this study involve medication?
Yes. The study involves medication, including CYB003.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 85 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
